Associated tags: Quality of life, COVID-19, Xanthine oxidase, Health, Patient, Coronavirus, ADPKD, Uric acid, Diabetic nephropathy, Therapy, Kidney disease, Pharmaceutical industry, Polycystic kidney disease
Locations: CANADA, COLORADO, UNITED STATES, NORTH AMERICA, NEW YORK CITY, CALGARY, AB, CA, KELLOGG, ALBERTA, BS, US, MASSACHUSETTS
Kidney disease,
University,
Xanthine oxidase,
Mouse,
Kidney,
Uric acid,
XO,
Prognosis,
American Journal,
Cyst,
Research,
Oxipurinol,
SUA,
Disease,
Patient,
Serum,
Polycystic kidney disease,
Therapy,
PKD,
Pharmaceutical industry This study shows, for the first time, that chronically increased SUA can significantly increase cyst index and increase kidney size in ADPKD.
Key Points:
- This study shows, for the first time, that chronically increased SUA can significantly increase cyst index and increase kidney size in ADPKD.
- Dr. Allen Davidoff, CEO of XORTX, stated, “We are pleased to have supported this pioneering research in polycystic kidney disease by Dr. Charles Edelstein of the University of Colorado.
- In human ADPKD, kidney size and declining kidney filtering capacity are correlated and are key indicators of disease progression and prognosis.
- These mechanistic studies are important for the planning of future clinical studies of xanthine oxidase inhibition in patients with ADPKD.”
Abbey,
Manager,
Biotechnology,
Pfizer,
Business,
Emergent,
Patient,
Vaccine,
Research,
Senior,
Psychology,
Kidney disease,
Biology,
Johns Hopkins University,
Therapy,
Industry Dive,
Pharmaceutical industry Abigail “Abbey” L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ: GMDA) and a member of its Board of Directors.
Key Points:
- Abigail “Abbey” L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ: GMDA) and a member of its Board of Directors.
- Ms. Jenkins brings over 20 years of leadership experience in the biopharmaceutical industry delivering life-enhancing therapies from research to commercialization for patients in need.
- Anthony Giovinazzo, XORTX’s Chairman of the Board commented, “We are delighted to welcome Abbey to the Board of Directors.
- Abbey is a highly skilled and experienced leader who will significantly contribute to the Board of Directors carrying out its mandate.
Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference, April 17-18
Key Points:
- Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference, April 17-18
Management will deliver a virtual presentation and will be available for virtual one-on-one meetings.
- CEM Scottsdale Capital Event in Scottsdale, April 19-21
Management will deliver a corporate update and be available for one-on-one meetings.
- The Company also announces it has engaged LHA Investor Relations for investor relations services for a fee of US$15,000 per month.
- The LHA Investor Relations agreement is for a term of six months, renewable by mutual consent and can be terminated by XORTX on 30 days’ notice.
Retrieved on:
Wednesday, March 27, 2024
Sanofi,
Database,
Internal medicine,
Critical Path Institute,
XRX,
TEMPO,
Patient,
Research,
Biomarker,
TAME,
Polycystic kidney disease,
National Institutes of Health,
MD,
Kidney disease,
European Medicines Agency,
Publication,
PKD,
Clinical trial,
Boston Medical Center,
Therapy,
Grady Memorial Hospital,
FDA,
Food,
Pharmaceutical industry CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease (“ADPKD”), is pleased to announce that Dr. Ronald Perrone has joined the Company’s Clinical Advisory Board.
Key Points:
- CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease (“ADPKD”), is pleased to announce that Dr. Ronald Perrone has joined the Company’s Clinical Advisory Board.
- Dr. Allen Davidoff stated, “We are excited that Dr. Ron Perrone has agreed to join XORTX’s Clinical Advisory Board.
- Dr. Perrone brings substantial medical and professional experience as a thought leader, combined with clinical experience treating patients with ADPKD and kidney disease.
- We are privileged to have Dr. Perrone join our esteemed Clinical Advisory Board alongside current members, Dr. Petter Bjornstad, Dr. Richard Johnson, Dr. Federico Maese, Dr. Anjay Rostogi and Dr. Charles Edelstein.
Consultant,
Nephrology,
Provisional application,
XRX,
Partnership,
Chemistry,
Kidney disease,
Tablet,
Orphan,
Bryant University,
University,
EMA,
Polycystic kidney disease,
Trial of the century,
Oxipurinol,
MBA,
GMP,
Diet,
PKD,
Treatment,
Society,
Therapy,
Patent,
Rensselaer Polytechnic Institute,
FDA,
Marketing,
Diagnosis,
American Society of Nephrology,
Uric acid,
Pharmaceutical industry Dr. Allen Davidoff, CEO of XORTX, stated, “2023 marked a year of substantial clinical, technological and regulatory progress, establishing the foundation for the Company’s 2024 goals.
Key Points:
- Dr. Allen Davidoff, CEO of XORTX, stated, “2023 marked a year of substantial clinical, technological and regulatory progress, establishing the foundation for the Company’s 2024 goals.
- Each of these milestones permit the next step in the Company’s clinical development plan, being a “registration” clinical trial – XRX-OXY-201 in pursuit of accelerated approval and support of the Company’s lead program XRx-008 program for ADPKD.
- Chemistry and Manufacturing, Clinical and Pre-Clinical Highlights – Produced drug substance for oxypurinol production and produced GMP drug substance; confirmed XORLO™ formulation, produced enhanced bioavailability and produced clinical supply of tablets for clinical trials.
- August 29, 2023 – XORTX submitted an Orphan Drug Designation application to the EMA for the treatment of ADPKD.
Retrieved on:
Wednesday, January 3, 2024
DN,
Immunoglobulin A,
IgA nephropathy,
Kidney disease,
Diabetic nephropathy,
Uric acid,
Trial of the century,
Oxipurinol,
Therapy,
Autosome,
Pharmacokinetics,
Focal segmental glomerulosclerosis,
Patent,
Chronic kidney disease,
ADPKD,
Treating,
Study,
Polycystic kidney disease,
XRX,
Safety,
Lupus nephritis,
XOI,
CKD,
Pharmaceutical industry CALGARY, Alberta, Jan. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces submission of a new patent for the treatment of chronic kidney disease (“CKD”).
Key Points:
- CALGARY, Alberta, Jan. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces submission of a new patent for the treatment of chronic kidney disease (“CKD”).
- This patent is designed to protect new discoveries and strategies for the treatment of individuals with varied degrees of kidney function in the setting of CKD.
- This patent application is intended to claim new opportunities to enhance how the xanthine oxidase inhibitor class of drugs may be dosed in the future.
- Importantly, how to further improve the safe and effective administration of this class of drugs, including oxypurinol.”
AMAG Pharmaceuticals,
Bryant University,
Nephrology,
Johnson & Johnson,
Kidney disease,
Rensselaer Polytechnic Institute,
MBA,
Therapy,
CSL Vifor,
Knowledge,
Laboratory,
Abbott Laboratories,
Pharmaceutical industry CALGARY, Alberta, Jan. 02, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Mr. Patrick Treanor to the Board of Directors and announces the resignation of Ian Klassen, both effective December 31, 2023.
Key Points:
- CALGARY, Alberta, Jan. 02, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Mr. Patrick Treanor to the Board of Directors and announces the resignation of Ian Klassen, both effective December 31, 2023.
- He previously served as President, US for Vifor Pharma, an international pharmaceutical company focused on nephrology.
- Mr. Treanor currently serves on the board of directors of KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors.
- Anthony Giovinazzo, Chair of XORTX, stated, “We are very pleased to have Patrick Treanor agree to join the XORTX board.
Retrieved on:
Thursday, November 30, 2023
TSX Venture Exchange,
Sale,
Form,
Kidney disease,
Register,
Therapy,
Prospectus,
ATM,
Market,
Commission,
Security (finance) A cash commission of 3.0% on the aggregate gross proceeds raised under the ATM Offering will be paid to Wainwright in connection with its services.
Key Points:
- A cash commission of 3.0% on the aggregate gross proceeds raised under the ATM Offering will be paid to Wainwright in connection with its services.
- The ATM Offering is being made in the United States pursuant to a registration statement on Form F-3 (File No.
- No Shares in the ATM Offering will be sold on the TSX Venture Exchange (“TSXV”) or any other trading market in Canada.
- If XORTX chooses to sell Shares under the ATM Offering, the Company intends to use the net proceeds of the ATM Offering for working capital and for other general corporate purposes.
Retrieved on:
Wednesday, November 29, 2023
CALGARY, Alberta, Nov. 29, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has received a letter of compliance from the Nasdaq Stock Market LLC’s ("Nasdaq”) Listing Qualifications Department in connection with Nasdaq Rule 5550(a)(2) that requires the shares to maintain a minimum bid price of US$1.00 per share (the “Minimum Bid Requirement”).
Key Points:
- CALGARY, Alberta, Nov. 29, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has received a letter of compliance from the Nasdaq Stock Market LLC’s ("Nasdaq”) Listing Qualifications Department in connection with Nasdaq Rule 5550(a)(2) that requires the shares to maintain a minimum bid price of US$1.00 per share (the “Minimum Bid Requirement”).
- In order to regain compliance, the Company’s common shares were required to trade at or above US$1.00 per share for at least 10 consecutive trading days.
- XORTX notes that a delisting letter from Nasdaq (for failure to comply with the Minimum Bid Requirement) was received on November 22, 2023, that outlined the Nasdaq appeal process.
- However, with compliance with the Minimum Bid Requirement having been achieved on November 28, 2023, and a letter of compliance subsequently having been sent by Nasdaq, there is no further action by XORTX required, and trading of the Company’s common shares on Nasdaq will continue.
Retrieved on:
Friday, November 10, 2023
The Consolidation has been approved by the TSX Venture Exchange (the “TSXV”) and follows approval of a consolidation of the Shares on the basis of a range of up to nine pre-consolidation Shares for every one post-consolidation Share at the special meeting of shareholders of the Company held on October 27, 2023.
Key Points:
- The Consolidation has been approved by the TSX Venture Exchange (the “TSXV”) and follows approval of a consolidation of the Shares on the basis of a range of up to nine pre-consolidation Shares for every one post-consolidation Share at the special meeting of shareholders of the Company held on October 27, 2023.
- As a result of the Consolidation, the number of issued and outstanding Shares will be reduced from 17,989,687 to approximately 1,998,854, subject to adjustment for rounding.
- No fractional shares will be issued in connection with the Consolidation.
- Until surrendered, each share certificate representing pre-Consolidation Shares will represent the number of whole post-Consolidation shares to which the holder is entitled as a result of the Consolidation.
